-
1
-
-
41349099104
-
Cancer statistics, 2007
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2008;58:71-96.
-
(2008)
CA Cancer J Clin
, vol.58
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
3
-
-
0032784783
-
WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997
-
Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3835-3849
-
-
Harris, N.1
Jaffe, E.2
Diebold, J.3
-
4
-
-
1542753559
-
Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
-
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21:4642-4649.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4642-4649
-
-
Cheson, B.D.1
Bennett, J.M.2
Kopecky, K.J.3
-
5
-
-
0037114753
-
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)
-
Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
-
(2002)
Blood
, vol.100
, pp. 4325-4336
-
-
Byrd, J.C.1
Mrozek, K.2
Dodge, R.K.3
-
6
-
-
33846876123
-
Acute myeloid leukemia carrying cytoplasmic/mutated nucleoplasmin (NPMc+ AML): Biologic and clinical correlates
-
Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleoplasmin (NPMc+ AML): biologic and clinical correlates. Blood 2007;109:874-885.
-
(2007)
Blood
, vol.109
, pp. 874-885
-
-
Falini, B.1
Nicoletti, I.2
Martelli, M.F.3
Mecucci, C.4
-
7
-
-
28444446313
-
Mutations in nucleophosmin (NPM) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
-
Verhaak R, Goudswaard C, Von Putten, et al. Mutations in nucleophosmin (NPM) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-3756.
-
(2005)
Blood
, vol.106
, pp. 3747-3756
-
-
Verhaak, R.1
Goudswaard, C.2
Putten, V.3
-
8
-
-
0037114829
-
-
Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
-
Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
-
-
-
-
9
-
-
14644438570
-
-
Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424. Erratum in Clin Cancer Res 2005;11:5659.
-
Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424. Erratum in Clin Cancer Res 2005;11:5659.
-
-
-
-
10
-
-
33748467435
-
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8:21): A Cancer and Leukemia Group B study
-
Paschka P, Marucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8:21): a Cancer and Leukemia Group B study. J Clin Oncol 2006;24:3904-3911.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3904-3911
-
-
Paschka, P.1
Marucci, G.2
Ruppert, A.S.3
-
11
-
-
33646432204
-
Prognostic impact of c-KIT mutation in core binding factor leukemias. An Italian retrospective study
-
Cairoli R, Beghini A, Grub G, et al. Prognostic impact of c-KIT mutation in core binding factor leukemias. An Italian retrospective study. Blood 2006;107:3463-3468.
-
(2006)
Blood
, vol.107
, pp. 3463-3468
-
-
Cairoli, R.1
Beghini, A.2
Grub, G.3
-
12
-
-
33344465478
-
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
-
Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:191-199.
-
(2006)
Blood
, vol.107
, pp. 191-199
-
-
Schnittger, S.1
Kohl, T.M.2
Haferlach, T.3
-
13
-
-
0023752982
-
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
-
Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: 567-572.
-
(1988)
Blood
, vol.72
, pp. 567-572
-
-
Huang, M.E.1
Ye, Y.C.2
Chen, S.R.3
-
14
-
-
0030923479
-
All-trans retinoic acid in acute promylocytic leukemia
-
Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promylocytic leukemia. N EnglJ Med 1997;337:1021-1028.
-
(1997)
N EnglJ Med
, vol.337
, pp. 1021-1028
-
-
Tallman, M.S.1
Andersen, J.W.2
Schiffer, C.A.3
-
15
-
-
0037115195
-
All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
-
Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-4302.
-
(2002)
Blood
, vol.100
, pp. 4298-4302
-
-
Tallman, M.S.1
Andersen, J.W.2
Schiffer, C.A.3
-
16
-
-
0027368561
-
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group
-
Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-3249.
-
(1993)
Blood
, vol.82
, pp. 3241-3249
-
-
Fenaux, P.1
Le Deley, M.C.2
Castaigne, S.3
-
17
-
-
0033566639
-
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
-
Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94: 1192-1200.
-
(1999)
Blood
, vol.94
, pp. 1192-1200
-
-
Fenaux, P.1
Chastang, C.2
Chevret, S.3
-
18
-
-
0030825408
-
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
-
Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-1021.
-
(1997)
Blood
, vol.90
, pp. 1014-1021
-
-
Mandelli, F.1
Diverio, D.2
Avvisati, G.3
-
19
-
-
0033230342
-
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia
-
Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia. Blood 1999;94:3015-3021.
-
(1999)
Blood
, vol.94
, pp. 3015-3021
-
-
Sanz, M.A.1
Martín, G.2
Rayón, C.3
-
20
-
-
0034663162
-
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
-
Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-1253.
-
(2000)
Blood
, vol.96
, pp. 1247-1253
-
-
Sanz, M.A.1
Lo Coco, F.2
Martin, G.3
-
21
-
-
10744220024
-
Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic-acid and anthracycline monotherapy: A multicenter study by the PETHEMA group
-
Sanz MA, Martin G, Gonzalez M, et al. Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic-acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-1243.
-
(2004)
Blood
, vol.103
, pp. 1237-1243
-
-
Sanz, M.A.1
Martin, G.2
Gonzalez, M.3
-
22
-
-
50049126426
-
Risk-adapted treatment of acute promyelocytic leukemia: Updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy [abstract]
-
Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia: updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy [abstract], Blood 2007;110:182a.
-
(2007)
Blood
, vol.110
-
-
Sanz, M.A.1
Montesinos, P.2
Vellenga, E.3
-
23
-
-
34247369329
-
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
-
Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006;24:5703-5710.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5703-5710
-
-
Ades, L.1
Chevret, S.2
Raffoux, E.3
-
24
-
-
38949092914
-
Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results
-
Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-1084.
-
(2008)
Blood
, vol.111
, pp. 1078-1084
-
-
Ades, L.1
Sanz, M.A.2
Chevret, S.3
-
25
-
-
0030610687
-
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
-
Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354-3360.
-
(1997)
Blood
, vol.89
, pp. 3354-3360
-
-
Shen, Z.-X.1
Chen, G.-Q.2
Ni, J.-H.3
-
26
-
-
0032487923
-
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
-
Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348.
-
(1998)
N Engl J Med
, vol.339
, pp. 1341-1348
-
-
Soignet, S.L.1
Maslak, P.2
Wang, Z.-G.3
-
27
-
-
11144355810
-
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
-
Shen Z, Shiz, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101: 5328-5335.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 5328-5335
-
-
Shen, Z.1
Shiz, F.J.2
-
28
-
-
33646386643
-
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated promyelocytic leukemia
-
Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated promyelocytic leukemia. Blood 2006;107:3469-3473.
-
(2006)
Blood
, vol.107
, pp. 3469-3473
-
-
Estey, E.1
Garcia-Manero, G.2
Ferrajoli, A.3
-
29
-
-
33751116539
-
Optimizing treatment for elderly patients with acute promyelocytic leukemia: Is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
-
Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 2006;47:2282-2288.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 2282-2288
-
-
Tsimberidou, A.M.1
Kantarjian, H.2
Keating, M.J.3
Estey, E.4
-
30
-
-
33847188550
-
Strategies for advanced APL: Long-term follow-up of arsenic therapy and new approaches
-
1:23-24
-
Tallman MS. Strategies for advanced APL: long-term follow-up of arsenic therapy and new approaches. Haematologica Reports 2005; 1:23-24.
-
Haematologica Reports 2005
-
-
Tallman, M.S.1
-
31
-
-
0037275493
-
Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count
-
Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Brit J Haematol 2003;120:266-270.
-
(2003)
Brit J Haematol
, vol.120
, pp. 266-270
-
-
Breccia, M.1
Carmosino, I.2
Diverio, D.3
-
33
-
-
2442588102
-
AIDA: The Italian way of treating APL [abstract]
-
Avvistai G, Petti MC, Lo Coco F, et al. AIDA: the Italian way of treating APL [abstract]. Blood 2003;102:142a,
-
(2003)
Blood
, vol.102
-
-
Avvistai, G.1
Petti, M.C.2
Lo Coco, F.3
-
34
-
-
16644373167
-
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group
-
de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005;23:120-126.
-
(2005)
J Clin Oncol
, vol.23
, pp. 120-126
-
-
de Botton, S.1
Fawaz, A.2
Chevret, S.3
-
35
-
-
4644293319
-
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
-
Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995-1999.
-
(2004)
Blood
, vol.104
, pp. 1995-1999
-
-
Lo-Coco, F.1
Cimino, G.2
Breccia, M.3
-
37
-
-
0031905441
-
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemic: A review and updated results from the Australian Leukemia Study Group
-
Bishop JF, Matthews JP, Young GA, et al. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemic: a review and updated results from the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315-321.
-
(1998)
Leuk Lymphoma
, vol.28
, pp. 315-321
-
-
Bishop, J.F.1
Matthews, J.P.2
Young, G.A.3
-
38
-
-
10244249096
-
A randomized investigation of high dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
-
Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-2851.
-
(1996)
Blood
, vol.88
, pp. 2841-2851
-
-
Weick, J.K.1
Kopecky, K.J.2
Appelbaum, F.R.3
-
39
-
-
0027941369
-
Intensive postremission chemotherapy in adults with acute myeloid leukemia
-
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
-
(1994)
N Engl J Med
, vol.331
, pp. 896-903
-
-
Mayer, R.J.1
Davis, R.B.2
Schiffer, C.A.3
-
40
-
-
34548136106
-
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
-
Al-Ali HK, Brand R, Van Biezen A, et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:1945-1951.
-
(2007)
Leukemia
, vol.21
, pp. 1945-1951
-
-
Al-Ali, H.K.1
Brand, R.2
Van Biezen, A.3
-
41
-
-
17544388046
-
Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
-
Bloomfield CD, Lawrence D, Byrd C, et al. Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
-
(1998)
Cancer Res
, vol.58
, pp. 4173-4179
-
-
Bloomfield, C.D.1
Lawrence, D.2
Byrd, C.3
-
42
-
-
0041737626
-
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial
-
Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 2003;102:1232-1240.
-
(2003)
Blood
, vol.102
, pp. 1232-1240
-
-
Suciu, S.1
Mandelli, F.2
de Witte, T.3
-
43
-
-
12944281160
-
High dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: Impact of cytogenetics on achieving a complete remission
-
Stein A, O'Donnell M, Slovak M, et al. High dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000;14:1191-1196.
-
(2000)
Leukemia
, vol.14
, pp. 1191-1196
-
-
Stein, A.1
O'Donnell, M.2
Slovak, M.3
-
44
-
-
20044371173
-
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study
-
Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:482-493.
-
(2005)
J Clin Oncol
, vol.23
, pp. 482-493
-
-
Farag, S.S.1
Ruppert, A.S.2
Mrozek, K.3
-
45
-
-
28444473100
-
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations
-
Döhner K, Schlenk RF, Habdank M. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-3746.
-
(2005)
Blood
, vol.106
, pp. 3740-3746
-
-
Döhner, K.1
Schlenk, R.F.2
Habdank, M.3
-
46
-
-
33644521267
-
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodysplastic syndrome
-
Kantarjian H, O'Brien S, Cortex J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodysplastic syndrome. Cancer 2006; 106:1090-1098.
-
(2006)
Cancer
, vol.106
, pp. 1090-1098
-
-
Kantarjian, H.1
O'Brien, S.2
Cortex, J.3
-
47
-
-
33947205565
-
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive chemotherapy
-
Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive chemotherapy. Cancer 2007;109:1114-1124.
-
(2007)
Cancer
, vol.109
, pp. 1114-1124
-
-
Burnett, A.K.1
Milligan, D.2
Prentice, A.G.3
-
48
-
-
33745191374
-
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
-
Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
-
(2006)
Blood
, vol.108
, pp. 63-73
-
-
Farag, S.S.1
Archer, K.J.2
Mrozek, K.3
-
49
-
-
48849109720
-
Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]
-
Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]. Blood 2007;110:55a.
-
(2007)
Blood
, vol.110
-
-
Pautas, C.1
Thomas, X.2
Merabet, F.3
-
50
-
-
35948934399
-
Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML) [abstract]
-
Cashen A, Schiller GJ, Larsen JS, et al. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML) [abstract]. Blood 2006;108:561a.
-
(2006)
Blood
, vol.108
-
-
Cashen, A.1
Schiller, G.J.2
Larsen, J.S.3
-
51
-
-
0141482004
-
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
-
Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
-
(2003)
Blood
, vol.102
, pp. 2379-2386
-
-
Kantarjian, H.1
Gandhi, V.2
Cortes, J.3
-
52
-
-
19944433802
-
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
-
Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947.
-
(2005)
Blood
, vol.105
, pp. 940-947
-
-
Faderl, S.1
Gandhi, V.2
O'Brien, S.3
-
53
-
-
34250157761
-
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
-
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-5135.
-
(2007)
Blood
, vol.109
, pp. 5129-5135
-
-
Gardin, C.1
Turlure, P.2
Fagot, T.3
-
54
-
-
33847263418
-
Can reduced-intensity allogeneic transplantation cure older adults with AML?
-
Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007;20: 85-90.
-
(2007)
Best Pract Res Clin Haematol
, vol.20
, pp. 85-90
-
-
Storb, R.1
-
55
-
-
33845573825
-
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with e novo acute myeloid leukemia
-
Herr AL, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with e novo acute myeloid leukemia. Leukemia 2007;21:129-135.
-
(2007)
Leukemia
, vol.21
, pp. 129-135
-
-
Herr, A.L.1
Labopin, M.2
Blaise, D.3
-
56
-
-
33846924515
-
Prospective feasibility analysis of reduced-intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
-
Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Blood 2007;109:1395-1400.
-
(2007)
Blood
, vol.109
, pp. 1395-1400
-
-
Estey, E.1
de Lima, M.2
Tibes, R.3
-
57
-
-
0036733277
-
Antibody targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
-
Larson RA, Boogaerts M, Estey E, et al. Antibody targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1027-1636.
-
(2002)
Leukemia
, vol.16
, pp. 1027-1636
-
-
Larson, R.A.1
Boogaerts, M.2
Estey, E.3
-
58
-
-
0029015209
-
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (< 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
-
Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (< 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
-
(1995)
Blood
, vol.86
, pp. 457-462
-
-
Rowe, J.M.1
Anderson, J.W.2
Mazza, J.J.3
|